NGcGM3/VSSP

3 trials

Sponsors

Center of Molecular Immunology (CIM)

Conditions

Metastatic hormone-receptor positive and HER2 negative breast cancerMetastatic melanomaSmall cell lung cancer

Phase 2

NGcGM3/VSSP in Metastatic melanoma

RecruitingRPCEC00000223

Center of Molecular Immunology (CIM)Metastatic melanoma

Start: 2014-03-11Target: 160Updated: 2026-03-30

NGcGM3/VSSP in small cell lung cancer

RecruitingRPCEC00000224

Center of Molecular Immunology (CIM)Small cell lung cancer

Start: 2017-04-01Target: 40Updated: 2026-03-30

Phase 3

NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer

Active, not recruitingRPCEC00000220

Center of Molecular Immunology (CIM)Metastatic hormone-receptor positive and HER2 negative breast cancer

Start: 2017-02-01Target: 286Updated: 2026-03-30